Management of advanced-stage peripheral T-cell lymphomas

Current Hematologic Malignancy Reports

Volumn 2, Issue 4, 2007, Pages 242-248

  Kimby, Eva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PENTOSTATIN; PRALATREXATE; PREDNISONE; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; ZANOLIMUMAB;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADVANCED CANCER; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANTIBIOTIC THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; ENTEROPATHY TYPE T CELL LYMPHOMA; GERIATRIC PATIENT; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; HYPOTENSION; HYPOXIA; IMMUNOPATHOLOGY; INFECTION; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PHENOTYPE; PROGNOSIS; REVIEW; SIDE EFFECT; SURVIVAL RATE; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUGS, INVESTIGATIONAL; FOLIC ACID ANTAGONISTS; GLYCOPROTEINS; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LYMPHOMA, T-CELL, PERIPHERAL; MICE; MICE, NUDE; MULTICENTER STUDIES AS TOPIC; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38349074221     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-007-0033-z     Document Type: Review

References (53)

1. Harris NL, Jaffe ES, Diebold J, et al.: Lymphoma classification - from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms [review]. Ann Oncol 2000, 11(Suppl 1):3-10.
2. Jaffe HN, Stein H (eds): Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2001.
3. Bruggemann M, White H, Gaulard P, et al.: Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies. Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia 2007, 21:215-221.
4. Shipp MA, Harrington DP, Anderson JR, et al.: A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
5. Gisselbrecht C, Gaulard P, Lepade E, et al.: Prognostic significance of T-cell phenotype in aggressive Non-Hodgkin's lymphomas. Blood 1998, 92:76-78.
6. Sonnen R, Schmidt W-P, Muller-Hermelink HK, Schmitz N: The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005, 129:366-372. Evaluation for prognostic factors, as the International Prognostic Index score is important also in peripheral T-cell lymphomas.
7. Escalon MP, Liu NS, Yang Y, et al.: Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer 2005, 103:2091-2098.
8. Gallamini A, Stelitano C, Calvi R, et al.: Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004, 103:2474-2479.
9. McKelvey EM, Gottlieb JA, Wilson HE, et al.: Hydroxyl-daunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976, 38:1484-1493.
10. Rüdiger T, Weisenburger DD, Anderson JR, et al.: Results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002, 13:140-149.
11. Melnyk A, Rodriguez A, Pugh WC, et al.: Evaluation of the Revised European-American Lymphoma Classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997, 89:4514-4520.
12. Jerkeman M, Anderson H, Cavallin-Stahl E, et al.: CHOP versus MACOP-B in aggressive lymphoma - a Nordic Lymphoma Group randomised trial. Ann Oncol 1999, 10:1079-1086.
13. Delmer A, Mounier N, Gaulard P, et al.: Intensified induction therapy with etoposide and high dose cytarabine in patients aged less than 60 years with peripheral T-cell and NK cell lymphoma. J Clin Oncol 2003, 22(suppl):591.
14. Gressin R, Peoch M, Deconinck E, et al.: The VIP-ABVD regimen is not superior to the CHOP 21 for the treatment of non epidermotropic peripheral T cell lymphoma. Final results of the "LTP95" protocol of the GOELAMS [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2464.
15. Pfreundschuh M, Truemper L, Kloess M, et al., and the German High-Grade Non-Hodgkin's Lymphoma Study Group: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004, 104:626-633.
16. Pfreundschuh M, Truemper L, Kloess M, et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634-641.
17. Kurzrock R, Ravandi F: Purine analogues in advanced T-cell lymphoid malignancies. Semin Hematol 2006, 43(Suppl 2):27-34. An interesting overview on the use of purine analogues.
18. Zinzani PL, Magagnoli M, Bendandi M, et al.: Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 1998, 9:1351-1353.
19. Rodriguez J, Munsell M, Yazji S, et al.: Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001, 19:3766-3770.
20. Song KW, Mollee P, Keating A, Crump M: Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003, 120:978-985.
21. Jantunen E, Wiklund T, Juvonen E, et al.: Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004, 33:405-410.
22. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al.: Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006, 134:202-207.
23. Rodriguez J, Conde E, Gutierrez A, et al.: The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007, 18:652-657.
24. Reimer P, Schertlin T, Rüdiger T, et al.: Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 2004, 5:304-311.
25. Corradini P, Tarella C, Zallio F, et al.: Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006, 20:1533-1538. An important study because of its long-term follow-up.
26. Rodriguez J, Conde E, Gutierrez A, et al.: Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007, 79:32-38.
27. Corradini P, Dodero A, Zallio F, et al.: Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004, 22:2172-2176.
28. Wulf GG, Hasenkamp J, Jung W, et al.: Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma [letter]. Bone Marrow Transplant 2005, 36:271-273.
29. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
30. Pfreundschuh M, Kloess M, Schmits R, et al.: Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 13.
31. Rossmann E, Lundin J, Lenkei R, et al.: Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001, 2:300-306.
32. Rodig SJ, Abramson JS, Pinkus GS, et al.: Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006, 12:7174-7192. New data of importance for evaluation of patients planned for alemtuzumab.
33. Chang ST, Lu CL, Chuang SS, et al.: CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leuk Lymphoma 2007, 48:117-121.
34. Enblad G, Hagberg H, Erlanson M, et al.: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004, 103:2920-2924.
35. Trumper LH, Hohloch K, Kloess M, et al.: CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1): feasibility and toxicity of a phase II trial of the German High Grade Non-Hodgkin's Lymphoma Group DSHNHL [abstract]. J Clin Oncol 24(18S):7538.
36. Weidmann E, Hess G, Krause SW, et al.: Combination chemoimmunotherapy using alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) is an effective first-line regimen in peripheral T-cell lymphomas [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 2640.
37. Gallamini A, Zaja F, Patti C, et al.: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL prospective multicenter trial. Blood 2007, In press. A prospective multicenter trial showing that alemtuzumab and CHOP (CHOP-C) is a feasible and effective regimen in PTCL, with mostly manageable infectious complications.
38. Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther 2007, 7:11-17.
39. Dang NH, Pro B, Hagemeister FB, et al.: Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 13:439-447.
40. Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 2006, 33(Suppl 3):11-16.
41. Kim YH, Duvic M, Obitz E, et al.: Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007, 109:4655-4662.
42. O'Connor OA: Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma. Br J Cancer 2006, 95(Suppl 1):7-12. Interesting data on a new drug.
43. Olsen EA, Kim YH, Kuzel TM, et al: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:3109-3115.
44. Wang ES, O'Connor O, She Y, et al.: Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003, 44:1027-1035.
45. O'Connor OA: Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 2006, 18:591-597.
46. Rizvi MA, Evens AM, Tallman MS, et al.: T-cell non-Hodgkin lymphoma [review]. Blood 2006, 107:1255-1264. This review includes a lot of relevant new data on PTCLs and is highly recommended.
47. Deconinck E, Lamy T, Foussard C, et al.: Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000, 109:736-742.
48. Gascoyne R, Aoun P, Wu D et al.: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999, 93:3913-3921.
49. Siegert W, Agthe A, Griesser H, et al.: Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 1992, 117:364-370.
50. Schmitz N, Prange E, Haferlach T, et al.: High-dose chemotherapy and autologous bone marrow transplantation in relapsing angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). Bone Marrow Transplant 1991, 8:503-550.
51. Schetelig J, Fetscher S, Reichle A, et al.: Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003, 88:1272-1278.
52. Rodriguez J, Conde E Gutierrez A: Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007, 78:290-296.
53. Advani R, Horwitz S, Zelenetz A, Horning SJ: Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 2007, 48:521-525.